Shanghai Fosun Pharma Moves Forward with Henlius Merger

Shanghai Fosun Pharmaceutical (Group) Co (HK:2196) has released an update.

Shanghai Fosun Pharmaceutical is progressing towards the privatization of Shanghai Henlius Biotech via a merger by absorption, having recently secured approval from China’s National Development and Reform Commission. The company is actively working with local authorities to fulfill additional pre-conditions necessary for the merger. The dispatch of the Composite Document has been delayed, with a new deadline set for May 2025.

For further insights into HK:2196 stock, check out TipRanks’ Stock Analysis page.